In 2339 adults with obesity without diabetes, weekly retatrutide for 80 weeks cut body weight by 23.7% (9 mg) and 25.0% (12 mg) vs 3.9% with placebo, and, in those with the conditions, reduced knee osteoarthritis pain and sleep apnoea events. GI effects were most common.
RCTn = 2,339
Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity